Adaptimmune Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGE IN EQUITY

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGE IN EQUITY - USD ($) $ in Thousands	Common stock	Additional paid in capital	Accumulated other comprehensive (loss) income	Accumulated deficit	Total
Balance at the beginning of the period, shares at Dec. 31, 2020	928,754,958
Balance at the beginning of the period at Dec. 31, 2020	$ 1,325	$ 935,706	$ (10,048)	$ (585,756)	$ 341,227
Increase (Decrease) in Stockholders' Equity
Issuance of shares upon exercise of stock options	$ 6	529			535
Issuance of shares upon exercise of stock options (in shares)	4,062,210
Other comprehensive gain			(176)		(176)
Share-based compensation expense		5,334			5,334
Net loss				(37,763)	(37,763)
Balance at the end of the period at Mar. 31, 2021	$ 1,331	941,569	(10,224)	(623,519)	309,157
Balance at the end of the period, shares at Mar. 31, 2021	932,817,168
Balance at the beginning of the period, shares at Dec. 31, 2020	928,754,958
Balance at the beginning of the period at Dec. 31, 2020	$ 1,325	935,706	(10,048)	(585,756)	341,227
Increase (Decrease) in Stockholders' Equity
Net loss					(76,831)
Balance at the end of the period at Jun. 30, 2021	$ 1,336	949,575	(10,385)	(662,587)	277,939
Balance at the end of the period, shares at Jun. 30, 2021	936,237,126
Balance at the beginning of the period, shares at Mar. 31, 2021	932,817,168
Balance at the beginning of the period at Mar. 31, 2021	$ 1,331	941,569	(10,224)	(623,519)	309,157
Increase (Decrease) in Stockholders' Equity
Issuance of shares upon exercise of stock options	$ 1	42			43
Issuance of shares upon exercise of stock options (in shares)	350,628
Issue of shares under At The Market sales agreement, net of commision and expenses	$ 4	2,515			2,519
Issue of shares under At The Market sales agreement, net of commision and expenses (in shares)	3,069,330
Other comprehensive gain			(161)		(161)
Share-based compensation expense		5,449			5,449
Net loss				(39,068)	(39,068)
Balance at the end of the period at Jun. 30, 2021	$ 1,336	949,575	(10,385)	(662,587)	$ 277,939
Balance at the end of the period, shares at Jun. 30, 2021	936,237,126
Balance at the beginning of the period, shares at Dec. 31, 2021	937,547,934				937,547,934
Balance at the beginning of the period at Dec. 31, 2021	$ 1,337	959,611	(11,142)	(743,846)	$ 205,960
Increase (Decrease) in Stockholders' Equity
Issuance of shares upon exercise of stock options	$ 5	30			35
Issuance of shares upon exercise of stock options (in shares)	3,318,072
Other comprehensive gain			1,829		1,829
Share-based compensation expense		5,586			5,586
Net loss				(50,265)	(50,265)
Balance at the end of the period at Mar. 31, 2022	$ 1,342	965,227	(9,313)	(794,111)	$ 163,145
Balance at the end of the period, shares at Mar. 31, 2022	940,866,006
Balance at the beginning of the period, shares at Dec. 31, 2021	937,547,934				937,547,934
Balance at the beginning of the period at Dec. 31, 2021	$ 1,337	959,611	(11,142)	(743,846)	$ 205,960
Increase (Decrease) in Stockholders' Equity
Net loss					(94,785)
Balance at the end of the period at Jun. 30, 2022	$ 1,387	980,204	(1,043)	(838,631)	$ 141,917
Balance at the end of the period, shares at Jun. 30, 2022	976,759,524				976,759,524
Balance at the beginning of the period, shares at Mar. 31, 2022	940,866,006
Balance at the beginning of the period at Mar. 31, 2022	$ 1,342	965,227	(9,313)	(794,111)	$ 163,145
Increase (Decrease) in Stockholders' Equity
Issuance of shares upon exercise of stock options	$ 1				1
Issuance of shares upon exercise of stock options (in shares)	759,336
Issue of shares under At The Market sales agreement, net of commision and expenses	$ 44	9,932			9,976
Issue of shares under At The Market sales agreement, net of commision and expenses (in shares)	35,134,182
Other comprehensive gain			8,270		8,270
Share-based compensation expense		5,045			5,045
Net loss				(44,520)	(44,520)
Balance at the end of the period at Jun. 30, 2022	$ 1,387	$ 980,204	$ (1,043)	$ (838,631)	$ 141,917
Balance at the end of the period, shares at Jun. 30, 2022	976,759,524				976,759,524